z-logo
Premium
Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells
Author(s) -
Di Angelantonio Silvia,
Giniatullin Rashid,
Costa Valeria,
Sokolova Elena,
Nistri Andrea
Publication year - 2003
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705337
Subject(s) - calcitonin gene related peptide , nicotinic agonist , neuroscience , chemistry , neuropeptide , neurotransmission , agonist , cholinergic , receptor , medicine , endocrinology , biology , biochemistry
One classical example of how neuropeptides can affect the function of ligand‐gated receptors is the modulation of neuronal nicotinic receptors (nAChRs) by substance P. The present review updates current understanding of this action by substance P and compares it with other neuropeptides more recently found to modulate nAChRs in the autonomic nervous system. Calcitonin gene‐related peptide (CGRP) and its N‐terminal fragments have been shown to exert complex inhibitory as well facilitatory actions on nAChRs. Fragments such as CGRP 1–4 , CGRP 1–5 and CGRP 1–6 rapidly and reversibly enhance agonist sensitivity of nAChRs without directly activating those receptors. Longer fragments or the full‐length peptide potently inhibit responses mediated by nAChRs via an apparently competitive‐type antagonism. This phenomenon differs from the substance P‐induced block, which is agonist use‐dependent and preferential towards large nicotinic responses. It is argued that the full‐length peptides CGRP and substance P might play distinct roles in the activity‐dependent modulation of cholinergic neurotransmission, by inhibiting background noise in the case of CGRP or by reducing excessive excitation in the case of substance P. Hence, multiple neuropeptide mechanisms may represent a wide array of fine‐tuning processes to regulate nicotinic synaptic transmission. The availability of novel CGRP derivatives with a strong enhancing action on nAChRs may offer new leads for the drug design targeted for potentiation of nAChRs in the autonomic nervous system as well as in the brain, a subject of interest to counteract the deficit of the nAChR function associated with neurodegenerative diseases like Alzheimer's and Parkinson's diseases.British Journal of Pharmacology (2003) 139 , 1061–1073. doi: 10.1038/sj.bjp.0705337

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here